Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29642
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKilkenny, Monique F-
dc.contributor.authorOlaiya, Muideen T-
dc.contributor.authorDalli, Lachlan L-
dc.contributor.authorKim, Joosup-
dc.contributor.authorAndrew, Nadine E-
dc.contributor.authorSanfilippo, Frank M-
dc.contributor.authorThrift, Amanda G-
dc.contributor.authorNelson, Mark-
dc.contributor.authorPearce, Christopher-
dc.contributor.authorSanders, Lauren-
dc.contributor.authorDewey, Helen-
dc.contributor.authorClissold, Benjamin-
dc.contributor.authorGrimley, Rohan-
dc.contributor.authorCadilhac, Dominique A-
dc.date2021-
dc.date.accessioned2022-03-31T22:50:02Z-
dc.date.available2022-03-31T22:50:02Z-
dc.date.issued2022-
dc.identifier.citationNeuroepidemiology 2022; 56(1): 66-74en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/29642-
dc.description.abstractTreatment with several therapeutic classes of medication is recommended for secondary prevention of stroke. We analyzed the associations between the number of classes of prevention medications supplied within 90 days after discharge for ischemic stroke (IS)/transient ischemic attack (TIA) and survival. This is a retrospective cohort study of adults with first-ever IS/TIA (2010-2014) from the Australian Stroke Clinical Registry individually linked with data from national pharmaceutical and Medicare claims. Exposure was the number of classes of recommended medications, i.e., blood pressure-lowering, antithrombotic, or lipid-lowering agents, supplied to patients within 90 days after discharge for IS/TIA. The longitudinal association between the number of classes of medications and survival was evaluated with Cox proportional hazards regression models using the landmark approach. A landmark date of 90 days after hospital discharge was used to separate exposure and outcome periods, and only patients who survived until this date were included. Of 8,429 patients (43% female, median age 74 years, 80% IS), 607 (7%) died in the year following 90 days after discharge. Overall, 56% of patients were supplied all 3 classes of medications, 28% 2 classes of medications, 11% 1 class of medications, and 5% no class of medications. Compared to patients supplied all 3 medication classes, adjusted hazard ratios for all-cause mortality ranged from 1.43 (95% confidence interval [CI]: 1.18-1.72) in those supplied 2 medication classes to 2.04 (95% CI: 1.44-2.88) in those supplied with no medication class. Treatment with all 3 classes of guideline-recommended medications within 90 days after discharge was associated with better survival. Ongoing efforts are required to ensure optimal pharmacological intervention for secondary prevention of stroke.en
dc.language.isoeng
dc.subjectAdherenceen
dc.subjectMedicationen
dc.subjectPopulation registeren
dc.subjectSecondary preventionen
dc.subjectStrokeen
dc.titleTreatment with Multiple Therapeutic Classes of Medication Is Associated with Survival after Stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeuroepidemiologyen
dc.identifier.affiliationSchool of Medicine, Griffith University, Birtinya, Queensland, Australia..en
dc.identifier.affiliationNeurosciences Department, Monash Health, Clayton, Victoria, Australia..en
dc.identifier.affiliationNeurosciences Department, Barwon Health, Geelong, Victoria, Australia..en
dc.identifier.affiliationSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia..en
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.affiliationPeninsula Clinical School, Monash University, Melbourne, Victoria, Australia..en
dc.identifier.affiliationSchool of Population and Global Health, The University of Western Australia, Perth, Washington, Australia..en
dc.identifier.affiliationMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia..en
dc.identifier.affiliationOutcome Health, Blackburn, Victoria, Australia..en
dc.identifier.affiliationDepartment of Neurosciences, St Vincent's Hospital, Fitzroy, Victoria, Australia..en
dc.identifier.affiliationEastern Health Clinical School, Monash University, Box Hill, Victoria, Australia..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34758474/en
dc.identifier.doi10.1159/000520823en
dc.type.contentTexten
dc.identifier.orcid0000-0002-3375-287Xen
dc.identifier.orcid0000-0002-4079-0428en
dc.identifier.orcid0000-0001-8162-682Xen
dc.identifier.pubmedid34758474
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Dec 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.